+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials



Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials



American Journal of Transplantation 19(5): 1545-1551



Although liver biopsy is the gold standard for assessing allograft health, its attendant risk has deterred its use in routine monitoring of stable liver transplant recipients during long-term follow-up. We utilized prospectively collected data on adverse events from 2 clinical trials of immunosuppression withdrawal to quantify the risk of liver biopsy in pediatric liver transplant recipients. The trials included 451 liver biopsies in 179 children. No biopsies led to bleeding requiring transfusion or intervention, suggesting a clinically significant bleeding risk of <0.8%. Complications were reported in 5.5% of biopsies (95% CI 3.6%-8.1%): 5.8% (21/363) of protocol biopsies and 4.5% (4/88) of for-cause biopsies (P = .80). Mild complications occurred in 1.8% of biopsies, moderate in 1.8%, and severe in 2.0%. The majority of complications (89%) resolved within 1 week. Six of 9 (67%) severe complications were related to biliary issues; 5 were episodes of cholangitis. Biopsy-related cholangitis occurred only in children with underlying biliary strictures. Overall, biopsy-related complications were infrequent and resolved quickly. Severe complications were rare, with occult biliary stricture as the dominant driver. Our study provides evidence for clinicians who are considering the risk vs benefit of surveillance liver biopsies in pediatric liver transplant recipients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066064450

Download citation: RISBibTeXText

PMID: 30614623

DOI: 10.1111/ajt.15255


Related references

Tu1838 Hepatic Steatosis in Pediatric Liver Transplant Recipients: Single-Center Review of Post-Transplant Liver Biopsies. Gastroenterology 146(5): S-1010, 2014

Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatric Transplantation 5(5): 359-364, 2001

Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort. Transplant Infectious Disease 20(1):, 2018

Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients. World Journal of Gastroenterology 20(34): 12217-12225, 2014

Long-term survival and its related factors in pediatric liver transplant recipients of shiraz transplant center, shiraz, iran in 2012. Hepatitis Monthly 13(7): E10257, 2013

Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. Pediatric Transplantation 9(6): 741-745, 2005

Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea. Yonsei Medical Journal 50(6): 784-788, 2009

Approaching operational tolerance in long-term pediatric liver transplant recipients receiving minimal immunosuppression. Transplantation Proceedings 29(1-2): 449-451, 1997

A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. Gut 56(2): 304-306, 2007

Long-term outcome of liver transplant recipients followed exclusively outside the surgical transplant center. Gastroenterology 118(4 Suppl 2 Part 1): AASLD A985, 2000

Prevalence and management of post-transplant anemia in long-term follow-up of Chinese kidney transplant recipients: a single-center report. European Journal of Medical Research 18: 45, 2013

Posttransplant metabolic syndrome in the withdrawal of immunosuppression in Pediatric Liver Transplant Recipients (WISP-R) pilot trial. American Journal of Transplantation 15(3): 779-785, 2015

Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clinical Transplantation 23(3): 329-336, 2009

Cardiovascular risk factors in a cohort of long term renal transplant recipients The importance of post transplant diabetes. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 925A, 2001

Surveillance renal transplant biopsies and subclinical rejection at three months post-transplant in pediatric recipients. Pediatric Transplantation 11(5): 536-539, 2007